Preparation and characterization of a novel starch-based interpolyelectrolyte complex as matrix for controlled drug release

Mostrar otras versiones (1)

A novel cationized starch-based interpolyelectrolyte complex (IPEC) was formed using kappa-carrageenan as the counter polyion. Characterization of the product by turbidity measurements and elemental analyses indicated a 1:1 interaction of the repeating units. FT-IR spectra for the IPEC showed some d...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Prado, H.J
Otros Autores: Matulewicz, M.C, Bonelli, P.R, Cukierman, A.L
Formato: Capítulo de libro
Lenguaje:Inglés
Publicado: 2009
Materias:
PH
Acceso en línea:Registro en Scopus
DOI
Handle
Registro en la Biblioteca Digital
Aporte de:Registro referencial: Solicitar el recurso aquí
Biblioteca Central Dr. Luis F. Leloir (FCEN) de Universidad de Buenos Aires
LEADER 09186caa a22013337a 4500
001 PAPER-8628
003 AR-BaUEN
005 20230518203826.0
008 190411s2009 xx ||||fo|||| 00| 0 eng|d
024 7 |2 scopus  |a 2-s2.0-67649432515 
024 7 |2 cas  |a ibuprofen, 15687-27-1, 79261-49-7; starch, 9005-25-8, 9005-84-9; Amylose, 9005-82-7; Carrageenan, 9000-07-1; Drug Carriers; Electrolytes; Ibuprofen, 15687-27-1; Pharmaceutical Preparations; Quaternary Ammonium Compounds; Starch, 9005-25-8; Tablets 
040 |a Scopus  |b spa  |c AR-BaUEN  |d AR-BaUEN 
030 |a CRBRA 
100 1 |a Prado, H.J. 
245 1 0 |a Preparation and characterization of a novel starch-based interpolyelectrolyte complex as matrix for controlled drug release 
260 |c 2009 
270 1 0 |m Matulewicz, M.C.; Departamento de Química Orgánica (CIHIDECAR-CONICET), Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, C1428EGA Buenos Aires, Argentina; email: cristina@qo.fcen.uba.ar 
506 |2 openaire  |e Política editorial 
504 |a Mundargi, R.C., Shelke, N.B., Rokhade, A.P., Patil, S.A., Aminabhavi, T.M., (2008) Carbohydr. Polym., 71, pp. 42-53 
504 |a Rowe, R.C., Sheskey, P.J., Owen, S.C., (2005) Handbook of Pharmaceutical Excipients. 5th ed., , Pharmaceutical Press, London, UK 
504 |a Dumoulin, Y., Alex, S., Szabo, P., Cartilier, L., Mateescu, M.A., (1998) Carbohydr. Polym., 37, pp. 361-370 
504 |a Ispas-Szabo, P., Ravenelle, F., Hassan, I., Preda, M., Mateescu, M.A., (2000) Carbohydr. Res., 323, pp. 163-175 
504 |a Mulhbacher, J., Ispas-Szabo, P., Lenaerts, V., Mateescu, M.A., (2001) J. Controlled Release, 76, pp. 51-58 
504 |a Hennink, W.E., van Nostrum, C.F., (2002) Adv. Drug Delivery Rev., 54, pp. 13-36 
504 |a Satish, C.S., Satish, K.P., Shivakumar, H.G., (2006) Indian J. Pharm. Sci., 68, pp. 133-140 
504 |a Clausen, A.E., Bernkop-Schnürch, A., (2001) J. Controlled Release, 75, pp. 93-105 
504 |a Lowman, M.A., Complexing Polymers in Drug Delivery (2000) Handbook of Pharmaceutical Controlled Release Technology, pp. 89-98. , Wise D.L. (Ed), Marcel Dekker, New York, USA 
504 |a Gupta, V.K., Hariharan, M., Weathley, T.A., Price, J.C., (2001) Eur. J. Pharm. Biopharm., 51, pp. 241-248 
504 |a Tapia, C., Escobar, Z., Costa, E., Sapag-Hagar, J., Valenzuela, F., Basualto, C., Gai, M.N., Yazdani-Pedram, M., (2004) Eur. J. Pharm. Biopharm., 57, pp. 65-75 
504 |a Prado, H.J., Matulewicz, M.C., Bonelli, P., Cukierman, A.L., (2008) Eur. J. Pharm. Biopharm., 70, pp. 171-178 
504 |a Moustafine, R.I., Kabanova, T.V., Kemenova, V.A., Van den Mooter, G., (2005) J. Controlled Release, 103, pp. 191-198 
504 |a Moustafine, R.I., Zaharov, I.M., Kemenova, V.A., (2006) Eur. J. Pharm. Biopharm., 63, pp. 26-36 
504 |a Moustafine, R.I., Kemenova, V.A., Van den Mooter, G., (2005) Int. J. Pharm., 294, pp. 113-120 
504 |a Meshali, M.M., Gabr, K.E., (1993) Int. J. Pharm., 89, pp. 177-181 
504 |a Matsuhiro, B., Rivas, P., (1993) J. Appl. Phycol., 5, pp. 45-51 
504 |a Zhang, M., Ju, B.Z., Zhang, S.F., Ma, W., Yang, J.Z., (2007) Carbohydr. Polym., 69, pp. 123-129 
504 |a Mizuno, A., Mitsuiki, M., Masao, M., (1998) J. Agric. Food Chem., 46, pp. 98-103 
504 |a Mitsuiki, M., Yamamoto, Y., Mizuno, A., Motoki, M., (1998) J. Agric. Food Chem., 46, pp. 3528-3534 
504 |a Lieberman, H.A., Lachman, L., (1980) Pharmaceutical Dosage Forms: Tablets. 1st ed., , Marcel Dekker, New York, USA 
504 |a (2007), The United States Pharmacopeia 30/National Formulary 25 USP 30/NF 25, United States Pharmacopeial Convention, USA; Capron, I., Yvon, M., Muller, G., (1996) Food Hydrocolloids, 10, pp. 239-244 
504 |a Li, J.Y., Yeh, A.I., (2001) J. Food Eng., 50, pp. 141-148 
504 |a Adebayo, S.A., Brown-Myrie, E., Itiola, O.A., (2008) Powder Technol., 181, pp. 98-103 
504 |a Huang, X., Brazel, C.S., (2001) J. Controlled Release, 73, pp. 121-136 
504 |a Peppas, N.A., (1985) Pharm. Acta Helv., 60, pp. 110-115 
504 |a Siepmann, J., Peppas, N.A., (2001) Adv. Drug Delivery Rev., 48, pp. 139-157 
504 |a Peppas, N.A., Sahlin, J.J., (1989) Int. J. Pharm., 57, pp. 169-172 
504 |a Allen, T., Particle Size Analysis by Image Analysis (2003) Powder Sampling and Particle Size Determination. 1st ed., pp. 142-207. , Elsevier B.V., Amsterdam, The Netherlands Chapter 3 
520 3 |a A novel cationized starch-based interpolyelectrolyte complex (IPEC) was formed using kappa-carrageenan as the counter polyion. Characterization of the product by turbidity measurements and elemental analyses indicated a 1:1 interaction of the repeating units. FT-IR spectra for the IPEC showed some differences in comparison with either IPEC constituents or physical mixture. The swelling of tablets obtained by direct compression was independent of pH, and a maximum value of 742% was attained after 24 h. The performance of the IPEC as matrix for controlled release of ibuprofen indicates that drug delivery takes place in a zero-order manner. Experimental dissolution data in the buffer stage were properly represented by a model accounting for contributions of Fickian diffusion and relaxation phenomena; this model suggests that the former predominates over the latter, for the modeled range. © 2009 Elsevier Ltd. All rights reserved.  |l eng 
536 |a Detalles de la financiación: Universidad de Buenos Aires, B041, X137 
536 |a Detalles de la financiación: Agencia Nacional de Promoción Científica y Tecnológica, PICT 06-14237 
536 |a Detalles de la financiación: National Council for Scientific Research 
536 |a Detalles de la financiación: Consejo Nacional de Investigaciones Científicas y Técnicas, PIP 5467 
536 |a Detalles de la financiación: This work was supported by grants of the National Research Council of Argentina (CONICET, PIP 5467), Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT, PICT 06-14237) and the University of Buenos Aires (X137 and B041). M.C.M., A.L.C., and P.R.B. are Research Members of CONICET. H.J.P. receives a Doctoral Fellowship from CONICET. 
593 |a Departamento de Química Orgánica (CIHIDECAR-CONICET), Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, C1428EGA Buenos Aires, Argentina 
593 |a PINMATE-Departamento de Industrias, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, C1428EGA Buenos Aires, Argentina 
593 |a Cátedra de Farmacotecnia II, Departamento de Tecnología Farmacéutica, Facultad de Farmacia y Bioquímica, Junín 956, C1113AAD Buenos Aires, Argentina 
690 1 0 |a CATIONIZED STARCH 
690 1 0 |a CONTROLLED RELEASE 
690 1 0 |a IBUPROFEN 
690 1 0 |a INTERPOLYELECTROLYTE COMPLEX 
690 1 0 |a KAPPA-CARRAGEENAN 
690 1 0 |a MATRIX SYSTEM 
690 1 0 |a CATIONIZED STARCH 
690 1 0 |a CONTROLLED RELEASE 
690 1 0 |a IBUPROFEN 
690 1 0 |a INTERPOLYELECTROLYTE COMPLEX 
690 1 0 |a KAPPA-CARRAGEENAN 
690 1 0 |a MATRIX SYSTEM 
690 1 0 |a DISSOLUTION 
690 1 0 |a STARCH 
690 1 0 |a TURBIDITY 
690 1 0 |a CONTROLLED DRUG DELIVERY 
690 1 0 |a BUFFER 
690 1 0 |a IBUPROFEN 
690 1 0 |a POLYELECTROLYTE 
690 1 0 |a STARCH 
690 1 0 |a ARTICLE 
690 1 0 |a CONTROLLED DRUG RELEASE 
690 1 0 |a DIFFUSION 
690 1 0 |a DISSOLUTION 
690 1 0 |a DRUG DELIVERY SYSTEM 
690 1 0 |a DRUG SYNTHESIS 
690 1 0 |a INFRARED SPECTROSCOPY 
690 1 0 |a MEASUREMENT 
690 1 0 |a PERFORMANCE 
690 1 0 |a PRIORITY JOURNAL 
690 1 0 |a TABLET 
690 1 0 |a TABLET MATRIX 
690 1 0 |a TURBIDITY 
690 1 0 |a AMYLOSE 
690 1 0 |a CARBOHYDRATE SEQUENCE 
690 1 0 |a CARRAGEENAN 
690 1 0 |a DIFFUSION 
690 1 0 |a DRUG CARRIERS 
690 1 0 |a ELECTROLYTES 
690 1 0 |a IBUPROFEN 
690 1 0 |a PHARMACEUTICAL PREPARATIONS 
690 1 0 |a QUATERNARY AMMONIUM COMPOUNDS 
690 1 0 |a SPECTROSCOPY, FOURIER TRANSFORM INFRARED 
690 1 0 |a STARCH 
690 1 0 |a TABLETS 
650 1 7 |2 spines  |a PH 
700 1 |a Matulewicz, M.C. 
700 1 |a Bonelli, P.R. 
700 1 |a Cukierman, A.L. 
773 0 |d 2009  |g v. 344  |h pp. 1325-1331  |k n. 11  |p Carbohydr. Res.  |x 00086215  |w (AR-BaUEN)CENRE-301  |t Carbohydrate Research 
856 4 1 |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-67649432515&doi=10.1016%2fj.carres.2009.04.026&partnerID=40&md5=d98e62634aed66b5582ead96efb367d0  |y Registro en Scopus 
856 4 0 |u https://doi.org/10.1016/j.carres.2009.04.026  |y DOI 
856 4 0 |u https://hdl.handle.net/20.500.12110/paper_00086215_v344_n11_p1325_Prado  |y Handle 
856 4 0 |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_00086215_v344_n11_p1325_Prado  |y Registro en la Biblioteca Digital 
961 |a paper_00086215_v344_n11_p1325_Prado  |b paper  |c PE 
962 |a info:eu-repo/semantics/article  |a info:ar-repo/semantics/artículo  |b info:eu-repo/semantics/publishedVersion 
963 |a VARI 
999 |c 69581 

Ejemplares similares